Open Orphan (ORPH) Notice of AGM September 12, 2019 – Posted in: Open Orphan (ORPH) – Tags: Annual General Meeting, Notice of AGM, open orphan (ORPH), Patient Advocacy Groups, rare and orphan drug, rphan drug services business

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company’s Annual General Meeting will be held on 2 October 2019 at 12 noon at Jeffreys Henry LLP, Finsgate, 5-7 Cranwood Street, London EC1V 9EE. A copy of the notice of Annual General Meeting has been sent to shareholders and is available from the Company’s website.

 

Enquiries:

Open Orphan Plc Tel: +353 (0)1 644 0007

Cathal Friel, Chief Executive Officer

 

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900

John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

 

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363

Anthony Farrell (Corporate Finance)

 

Camarco (Financial PR) Tel: +44 (0)20 3757 4980

Tom Huddart / Billy Clegg / Daniel Sherwen

 

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.